Capturing the enthesitis related arthritis contemporary profile of Caucasian patients in the era of biologics

Deligeorgakis, Dimitrios; Trachana, Maria; Pratsidou-Gertsi, Polyxeni; Dimopoulou, Despoina; Haidich, Anna‐Bettina; Garyfallos, Alexandros

doi:10.1007/s00296-020-04581-w

Cited by 5 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early hip and ankle involvement in ERA has been shown to be related with poor outcomes 6 . In another study, the presence of sacroiliitis in ERA patients was associated with increased biologic agent use and decreased clinical remission rates 22 . Goirand et al 3 reported a low rate of symptomatic axial disease at the time of diagnosis, but 60% of 114 ERA patients developed axial involvement in the fifth year of follow-up.…”

Section: Discussionmentioning

confidence: 99%

“…6 In another study, the presence of sacroiliitis in ERA patients was associated with increased biologic agent use and decreased clinical remission rates. 22 Goirand et al 3 reported a low rate of symptomatic axial disease at the time of diagnosis, but 60% of 114 ERA patients developed axial involvement in the fifth year of follow-up. In our study, those with active disease at 6 months had numerically less sacroiliitis than those with inactive disease.…”

Section: Discussionmentioning

confidence: 99%

“…25 In another study with 43 ERA patients, it was reported that JSpADA was also 0 points in patients in remission, similar to JADAS. 22 This suggests that a persistently higher JSpADA value during follow-up, rather than the JSpADA value at the time of diagnosis, is one of the predictive factors of active disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Juvenile Spondyloarthritis Disease Activity Index Is a Useful Tool in Enthesitis-Related Arthritis

et al. 2023

View full text Add to dashboard Cite

Objective To compare enthesitis-related arthritis (ERA) patients with active and inactive disease at 6 months and define baseline predictors for disease inactivity. In addition, to evaluate the demographic, clinical, and laboratory characteristics of ERA patients and to identify the real-life impact of the Juvenile Spondyloarthritis Disease Activity Index (JSpADA) in predicting active disease in ERA. Methods This medical record review study was conducted with 56 patients who were diagnosed with ERA at our clinic between June 2009 and June 2022. Demographic and clinical characteristics, laboratory parameters, treatment, and JSpADA were recorded. Results The patients were divided into 2 groups as active (n = 34) and inactive (n = 22) according to their disease activity at the sixth month. Sex, age at diagnosis, number and type of affected joints, and presence of sacroiliitis were similar in both groups. There was no difference in baseline erythrocyte sedimentation rate, but there was a significant difference in erythrocyte sedimentation rate at the third month (p = 0.52 and p = 0.018, respectively). The median JSpADA values at disease onset were 3.5 (interquartile range [IQR], 3–4.5) and 3.3 (IQR, 2.5–4) in the active and inactive groups, respectively (p = 0.27). At the third month, the median JSpADA values were 1.5 (IQR, 0.5–2.1) in the active group and 0.5 (IQR, 0.5–1.5) in the inactive group (p = 0.037). The cutoff value for JSpADA at the third month for active disease persisting at the sixth month was determined as 1 point (area under the curve, 0.662 ± 0.06; p = 0.042; 95% confidence interval, 0.51–0.80) by receiver operating characteristic curve analysis. Conclusion In ERA patients, a persistently high JSpADA value at follow-up is a predictive factor for active disease at the sixth month.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Juvenile Spondyloarthritis Disease Activity Index Is a Useful Tool in Enthesitis-Related Arthritis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The JSpADA has been accepted by the pediatric rheumatology community, as evidenced by usage in several subsequent studies. [5][6][7] A limitation to any data collection instrument is that it is only as good as the completeness of the data that are collected. For example, a recent study using the Pediatric Rheumatology International Trials Organisation registry documented that only 52% to 61% of critical data elements were collected in the database.…”

mentioning

confidence: 99%